- Home
- LTC vs GERN Comparison
LTC vs GERN Comparison
Compare LTC & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTC
- GERN
- Stock Information
- Founded
- LTC 1992
- GERN 1990
- Country
- LTC United States
- GERN United States
- Employees
- LTC N/A
- GERN N/A
- Industry
- LTC Real Estate Investment Trusts
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- LTC Real Estate
- GERN Health Care
- Exchange
- LTC Nasdaq
- GERN Nasdaq
- Market Cap
- LTC 1.6B
- GERN 1.5B
- IPO Year
- LTC 1992
- GERN 1996
- Fundamental
- Price
- LTC $35.45
- GERN $1.59
- Analyst Decision
- LTC Buy
- GERN Buy
- Analyst Count
- LTC 4
- GERN 11
- Target Price
- LTC $38.25
- GERN $5.80
- AVG Volume (30 Days)
- LTC 341.1K
- GERN 14.3M
- Earning Date
- LTC 04-28-2025
- GERN 05-01-2025
- Dividend Yield
- LTC 6.42%
- GERN N/A
- EPS Growth
- LTC N/A
- GERN N/A
- EPS
- LTC 2.04
- GERN N/A
- Revenue
- LTC $201,599,000.00
- GERN $76,994,000.00
- Revenue This Year
- LTC N/A
- GERN $208.83
- Revenue Next Year
- LTC $3.53
- GERN $57.49
- P/E Ratio
- LTC $17.41
- GERN N/A
- Revenue Growth
- LTC 5.10
- GERN 32386.92
- 52 Week Low
- LTC $31.14
- GERN $1.46
- 52 Week High
- LTC $39.89
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- LTC 53.85
- GERN 32.05
- Support Level
- LTC $34.77
- GERN $1.63
- Resistance Level
- LTC $35.30
- GERN $1.89
- Average True Range (ATR)
- LTC 0.53
- GERN 0.11
- MACD
- LTC -0.05
- GERN 0.03
- Stochastic Oscillator
- LTC 58.01
- GERN 16.67
About LTC LTC Properties Inc.
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in seniors housing and healthcare facilities through mortgage loans, property lease transactions, and other investments. Its real estate investments includes different types of properties such as Independent living communities, Assisted living communities, Memory care communities, Skilled nursing centers and other types of properties.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.